A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L

West Japan Oncology Group

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)

Abstract

In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel (CbP) showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of TC. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.

Original languageEnglish
Pages (from-to)363-368
Number of pages6
JournalAnnals of Oncology
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L'. Together they form a unique fingerprint.

Cite this